DE602008003522D1 - Feste zubereitung mit alogliptin und pioglitazon - Google Patents

Feste zubereitung mit alogliptin und pioglitazon

Info

Publication number
DE602008003522D1
DE602008003522D1 DE602008003522T DE602008003522T DE602008003522D1 DE 602008003522 D1 DE602008003522 D1 DE 602008003522D1 DE 602008003522 T DE602008003522 T DE 602008003522T DE 602008003522 T DE602008003522 T DE 602008003522T DE 602008003522 D1 DE602008003522 D1 DE 602008003522D1
Authority
DE
Germany
Prior art keywords
alogliptin
pioglitazone
solid preparation
preparation
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008003522T
Other languages
English (en)
Inventor
Kenji Nakamura
Kenichiro Kiyoshima
Junya Nomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602008003522(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE602008003522D1 publication Critical patent/DE602008003522D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602008003522T 2007-02-01 2008-01-30 Feste zubereitung mit alogliptin und pioglitazon Active DE602008003522D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (en) 2007-02-01 2008-01-30 Solid preparation comprising alogliptin and pioglitazone

Publications (1)

Publication Number Publication Date
DE602008003522D1 true DE602008003522D1 (de) 2010-12-30

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008003522T Active DE602008003522D1 (de) 2007-02-01 2008-01-30 Feste zubereitung mit alogliptin und pioglitazon

Country Status (39)

Country Link
US (1) US8637079B2 (de)
EP (1) EP2107905B1 (de)
JP (1) JP5284968B2 (de)
KR (1) KR101486091B1 (de)
CN (1) CN101646420B (de)
AR (1) AR065097A1 (de)
AT (1) ATE488227T1 (de)
AU (1) AU2008211981B2 (de)
BR (1) BRPI0807453B8 (de)
CA (1) CA2677201C (de)
CL (1) CL2008000279A1 (de)
CR (1) CR10992A (de)
CY (1) CY1111264T1 (de)
DE (1) DE602008003522D1 (de)
DK (1) DK2107905T3 (de)
DO (1) DOP2009000195A (de)
EA (1) EA015180B1 (de)
EC (1) ECSP099608A (de)
ES (1) ES2354397T3 (de)
GE (1) GEP20125410B (de)
HK (1) HK1138188A1 (de)
HR (1) HRP20110094T8 (de)
IL (1) IL200108A (de)
JO (1) JO2650B1 (de)
MA (1) MA31169B1 (de)
ME (1) ME01239B (de)
MX (1) MX2009008100A (de)
MY (1) MY147596A (de)
NZ (1) NZ579008A (de)
PE (1) PE20081663A1 (de)
PL (1) PL2107905T3 (de)
PT (1) PT2107905E (de)
RS (1) RS51592B (de)
SI (1) SI2107905T1 (de)
TN (1) TN2009000317A1 (de)
TW (2) TW201350143A (de)
UA (1) UA95828C2 (de)
WO (1) WO2008093882A1 (de)
ZA (1) ZA200905621B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
WO2009011451A1 (en) 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201201509A1 (ru) * 2010-05-05 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические составы, содержащие пиоглитазон и линаглиптин
EP3725325B1 (de) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetestherapie
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
EP3310357A1 (de) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Alogliptinformulierungen
RU2697836C2 (ru) * 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK0559702T3 (da) 1990-11-27 1995-05-15 Byk Gulden Lomberg Chem Fab Urapidil-slow-release-præparat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
DE60132723T2 (de) 2000-01-21 2009-01-29 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20060286168A1 (en) * 2002-07-11 2006-12-21 Masahiko Koike Process for producing coated preparation
IN192749B (de) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
WO2004067001A1 (ja) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
ES2556244T3 (es) * 2003-10-31 2016-01-14 Takeda Pharmaceutical Company Limited Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
LT3366283T (lt) 2004-01-20 2021-12-10 Novartis Ag Tiesioginio presavimo formulė ir procesas
CN102134229B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
AU2005299808B2 (en) 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
GEP20105033B (en) * 2005-12-28 2010-06-25 Takeda Pharmaceuticals Co Therapeutic agent for diabetes

Also Published As

Publication number Publication date
BRPI0807453B1 (pt) 2021-01-05
AU2008211981A1 (en) 2008-08-07
IL200108A (en) 2012-02-29
AU2008211981B2 (en) 2012-09-20
BRPI0807453B8 (pt) 2021-05-25
PE20081663A1 (es) 2008-12-25
CA2677201A1 (en) 2008-08-07
BRPI0807453A2 (pt) 2014-05-20
ECSP099608A (es) 2009-09-29
WO2008093882A1 (en) 2008-08-07
CL2008000279A1 (es) 2008-08-18
KR101486091B1 (ko) 2015-01-23
CN101646420A (zh) 2010-02-10
ES2354397T3 (es) 2011-03-14
HK1138188A1 (en) 2010-08-20
CN101646420B (zh) 2012-11-07
CR10992A (es) 2009-09-16
EA200970726A1 (ru) 2010-02-26
GEP20125410B (en) 2012-02-27
TW200836775A (en) 2008-09-16
CY1111264T1 (el) 2015-08-05
SI2107905T1 (sl) 2011-03-31
EA015180B1 (ru) 2011-06-30
ZA200905621B (en) 2010-10-27
TW201350143A (zh) 2013-12-16
NZ579008A (en) 2012-02-24
RS51592B (en) 2011-08-31
IL200108A0 (en) 2010-04-15
JO2650B1 (en) 2012-06-17
ME01239B (me) 2013-06-20
MX2009008100A (es) 2009-08-07
EP2107905B1 (de) 2010-11-17
HRP20110094T8 (en) 2011-07-31
PT2107905E (pt) 2010-12-17
AR065097A1 (es) 2009-05-13
TN2009000317A1 (en) 2010-12-31
US20100092551A1 (en) 2010-04-15
EP2107905A1 (de) 2009-10-14
PL2107905T3 (pl) 2011-04-29
MA31169B1 (fr) 2010-02-01
UA95828C2 (ru) 2011-09-12
HRP20110094T1 (hr) 2011-03-31
CA2677201C (en) 2015-11-17
DOP2009000195A (es) 2009-08-31
MY147596A (en) 2012-12-31
JP2010517937A (ja) 2010-05-27
TWI453041B (zh) 2014-09-21
KR20090109115A (ko) 2009-10-19
US8637079B2 (en) 2014-01-28
ATE488227T1 (de) 2010-12-15
DK2107905T3 (da) 2011-01-31
JP5284968B2 (ja) 2013-09-11

Similar Documents

Publication Publication Date Title
ATE488227T1 (de) Feste zubereitung mit alogliptin und pioglitazon
NL300891I2 (nl) Lotilaner en zouten daarvan
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
BRPI0819573A2 (pt) Composição e artigo
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0913822A2 (pt) forma farmacêutica oral e uso da forma farmacêutica
BRPI0922486A2 (pt) microcápsulas e suas respectivas utilizações
FI20075881A (fi) Lääketieteellinen väline ja sen valmistus
FI20086253A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0716893A2 (pt) Forma de dosagem sólida de olmesartan medoxomila e anlodipina
BRPI0918328A2 (pt) composição e artigo
FI20086250A (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0913807A2 (pt) composição e artigo
IL208771A0 (en) Iminopyridine derivatives and use thereof
SMT201500273B (it) Diidroetorfine e loro preparazione
ATE541462T1 (de) Insektizide kombinationen umfassend abamectin und cyflumetofen
DK2310383T3 (da) 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf
FR2917418B1 (fr) Composition de securite, non photocopiable et authentifiable
DK2032474T3 (da) Materialehåndtering og -behandling
DE112008004261A5 (de) Schichtabscheidevorrichtung und Schichtabscheideverfahren
BRPI0922008A2 (pt) compostos e respectivos metodos de preparação
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
AT504332B8 (de) Chokerseil und chokerseilsystem